Treatment of intestinal dysbiosis with immunoglobin
US11319361B2 · kind B2 · utility
0Cited by
3References
17Claims
0Family size
Inventor
Key dates
| Filing date | Nov 8, 2019 |
| Grant date | May 3, 2022 |
| Priority date | — |
| Expiry date | Jul 31, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A process is provided for inhibiting symptoms of intestinal dysbiosis in a subject that includes the oral administration to the subject suffering from intestinal dysbiosis an IgA, IgM, or a combination thereof. When administered in a therapeutic quantity based on the subject characteristics and the type of IgA or IgM, symptoms of intestinal dysbiosis in that subject are inhibited. Even non-secretory forms of IgA or IgM are effective when administered orally.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.